CLDX: Celldex Therapeutics, Inc.
About
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Key Details
Market Cap
$1.66B
P/E Ratio
-9.73
1Y Stock Return
-10.82%
1Y Revenue Growth
128.55%
Dividend Yield
0.00%
Price to Book
2.1
Strategies that include CLDX
Stock's related to CLDX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KRYS | 57.99% | $5.12B | +75.65% | 0.00% |
| ITRI | 49.63% | $5.19B | +76.91% | 0.00% |
| ALT | 42.41% | $531.30M | +194.09% | 0.00% |
| NTLA | 39.66% | $1.44B | -50.35% | 0.00% |
| DMRC | 39.63% | $694.39M | -2.06% | 0.00% |
| PRTA | 38.78% | $756.01M | -56.52% | 0.00% |
| EDIT | 37.13% | $204.72M | -75.49% | 0.00% |
| BEAM | 37.07% | $2.09B | -9.52% | 0.00% |
| NRIX | 36.79% | $1.61B | +269.37% | 0.00% |
| DAWN | 36.75% | $1.36B | +13.42% | 0.00% |
| SNDX | 35.83% | $1.35B | +2.87% | 0.00% |
| ATXS | 35.44% | $550.23M | +114.29% | 0.00% |
| CRNX | 35.02% | $5.12B | +84.27% | 0.00% |
| ACAD | 34.76% | $2.70B | -27.80% | 0.00% |
| PGEN | 34.75% | $228.91M | -28.00% | 0.00% |
| PLRX | 34.58% | $778.32M | -9.55% | 0.00% |
| KYMR | 34.52% | $2.77B | +125.95% | 0.00% |
| SDGR | 33.98% | $1.38B | -35.46% | 0.00% |
| ATUS | 33.95% | $1.10B | -0.42% | 0.00% |
| ATNM | 33.87% | $44.30M | -67.05% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TIGR | 0.01% | $869.81M | +19.38% | 0.00% |
| CQP | -0.03% | $25.90B | -6.77% | 5.96% |
| WST | 0.04% | $22.02B | -13.73% | 0.27% |
| SITC | 0.05% | $847.27M | +59.73% | 2.42% |
| ACIC | 0.07% | $631.49M | +58.21% | 0.00% |
| MANU | -0.10% | $2.88B | -9.41% | 0.00% |
| SEVN | 0.12% | $193.74M | +16.70% | 10.77% |
| MNR | -0.13% | $1.66B | -10.71% | 15.90% |
| ARQ | 0.16% | $332.89M | +216.80% | 0.00% |
| TEO | 0.20% | $1.69B | +87.97% | 0.00% |
| DESP | 0.23% | $1.16B | +111.97% | 0.00% |
| AFL | -0.27% | $61.74B | +35.69% | 1.35% |
| ED | 0.33% | $33.59B | +7.16% | 3.43% |
| TMUS | 0.34% | $270.63B | +56.92% | 0.83% |
| RILY | 0.35% | $145.72M | -79.86% | 20.75% |
| LICY | -0.36% | $53.41M | -60.56% | 0.00% |
| POST | -0.36% | $6.45B | +28.40% | 0.00% |
| NAPA | 0.38% | $1.63B | +9.61% | 0.00% |
| TLPH | -0.39% | $11.41M | +9.85% | 0.00% |
| TKC | -0.43% | $5.80B | +35.51% | 1.30% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| EW | -12.77% | $41.40B | +4.84% | 0.00% |
| SEG | -11.65% | $319.72M | +12.41% | 0.00% |
| WM | -11.47% | $87.92B | +27.58% | 1.34% |
| GAN | -10.68% | $83.39M | +21.19% | 0.00% |
| HUSA | -9.60% | $16.69M | -11.56% | 0.00% |
| SBUX | -9.02% | $111.45B | -5.15% | 2.37% |
| MSDL | -8.91% | $1.83B | +0.66% | 7.26% |
| PULM | -8.73% | $19.83M | +202.98% | 0.00% |
| K | -8.27% | $27.77B | +52.50% | 2.79% |
| IMNN | -8.01% | $10.02M | -22.89% | 0.00% |
| VERX | -7.98% | $7.99B | +89.70% | 0.00% |
| CYCN | -7.86% | $4.77M | -16.19% | 0.00% |
| IFF | -7.75% | $22.74B | +20.83% | 2.25% |
| TCTM | -7.66% | $8.10M | -42.99% | 0.00% |
| KR | -7.39% | $42.03B | +35.08% | 2.11% |
| CCEC | -7.12% | $1.02B | +28.03% | 3.26% |
| RSG | -6.96% | $66.05B | +31.79% | 1.04% |
| LNG | -6.95% | $49.37B | +24.99% | 0.82% |
| CANG | -6.95% | $253.50M | +212.50% | 0.00% |
| PRT | -6.79% | $48.72M | -16.56% | 10.33% |
ETF's related to CLDX
News
Yahoo
HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. “The introduction of our first bispecific candidat
Yahoo
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: Guggenheim Healthcare Innovation Conference on Tuesday, November 12th at 4:00 p.m. ET 7th Annual Evercore HealthCONx Conference on Tuesday, December 3rd at 4:15 p.m. ET Live webcasts of the presentations will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex websi
Yahoo
Celldex Therapeutics ( NASDAQ:CLDX ) Third Quarter 2024 Results Key Financial Results Net loss: US$42.1m (loss widened...
Yahoo
Celldex (CLDX) delivered earnings and revenue surprises of 7.25% and 121.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
HAMPTON, N.J. (AP) — Celldex Therapeutics Inc. CLDX) on Wednesday reported a loss of $42.1 million in its third quarter. On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 64 cents.
Yahoo
Enrollment continues in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentAll primary and secondary endpoints met with high statistical significance in global Phase 2 CIndU study Long term 52 week treatment data in landmark, global Phase 2 CSU study demonstrated deepening of response and a favorable safety profile Enrollment continues in Phase 2 PN and EOE studies; Phase 2 AD study to start in Q4 Celldex’s first bispecific for inflammatory diseases, CDX-622, to enter t
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.